Tufts University, Department of Biomedical Engineering, 4 Colby Street, Medford, MA 02155, USA.
Biomaterials. 2014 Jan;35(1):83-91. doi: 10.1016/j.biomaterials.2013.09.053. Epub 2013 Oct 4.
Over the past 30 years, silk has been proposed for numerous biomedical applications that go beyond its traditional use as a suture material. Silk sutures are well tolerated in humans, but the use of silk for vascular engineering applications still requires extensive biocompatibility testing. Some studies have indicated a need to modify silk to yield a hemocompatible surface. This study examined the potential of low molecular weight heparin as a material for refining silk properties by acting as a carrier for vascular endothelial growth factor (VEGF) and improving silk hemocompatibility. Heparinized silk showed a controlled VEGF release over 6 days; the released VEGF was bioactive and supported the growth of human endothelial cells. Silk samples were then assessed using a humanized hemocompatibility system that employs whole blood and endothelial cells. The overall thrombogenic response for silk was very low and similar to the clinical reference material polytetrafluoroethylene. Despite an initial inflammatory response to silk, apparent as complement and leukocyte activation, the endothelium was maintained in a resting, anticoagulant state. The low thrombogenic response and the ability to control VEGF release support the further development of silk for vascular applications.
在过去的 30 年中,丝已经被提议用于许多超越其作为缝合材料的传统用途的生物医学应用。丝缝线在人类中具有良好的耐受性,但丝在血管工程应用中的使用仍需要广泛的生物相容性测试。一些研究表明需要对丝进行改性以获得具有良好血液相容性的表面。本研究探讨了低分子量肝素作为一种通过充当血管内皮生长因子(VEGF)的载体并改善丝血液相容性来改善丝性能的材料的潜力。肝素化丝在 6 天内显示出受控的 VEGF 释放;释放的 VEGF 具有生物活性并支持人内皮细胞的生长。然后使用采用全血和内皮细胞的人源化血液相容性系统评估丝样品。丝的整体血栓形成反应非常低,与临床参考材料聚四氟乙烯相似。尽管丝最初会引起炎症反应,表现为补体和白细胞激活,但内皮细胞仍处于静止、抗凝状态。低血栓形成反应和控制 VEGF 释放的能力支持进一步开发丝用于血管应用。